Archive

HIGHLIGHTS

 
LSP co-leads € 40 million ($ 46.3 million) Series A in Egle Therapeutics
Egle will develop first-in-class immunotherapies targeting suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases Ser[...]
 
MD Anderson and SNIPR BIOME collaborate
to advance next-generation CRISPR microbiome therapeutics   Research focused on improving immunotherapy-related side effects for patients [...]
 
LSP invests in $83 Million Series A Financing of Evommune
To advance Development of a Unique Chronic Inflammation Pipeline Series A Comprises a Global Syndicate o Investors Including LSP, Pivotal[...]
 
LSP Portfolio Company Cardior Announces €64 M Series B Financing
Oversubscribed round enables late-stage clinical development of lead candidate, a micro-RNA-132 inhibitor, in heart failure and further acceler[...]
 
LSP portfolio company Nouscom announces
first patient dosed in a Phase 1b Trial with NOUS-PEV, a novel personalized cancer immunotherapy, in advanced melanoma or lung cancer   Am[...]
 
LSP leads $20 million financing of Visus Therapeutics
to advance clinical and commercial development of BRIMOCHOL™ for presbyopia     Amsterdam, The Netherlands, 10 August 2021 – LSP,[...]
 
LSP Invests in $110 Million Series B Financing of T-knife Therapeutics
Plan to initiate the IMAG1NE Phase 1/2 clinical study of TK-8001, a TCR-T cell therapy for MAGE-A1 positive solid tumors, in 2021    [...]
 
LSP Portfolio Company Artios Announces $ 153 Million (£ 110 Million) Series C Fina...
Funding propels Artios’ ability to progress beyond synthetic lethality and to continue the exploitation of the full spectrum of oncology vuln[...]
 
LSP’s Portfolio Company XyloCor Therapeutics Commences Phase 2 Component
of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina   Independent Data Monitoring Committee authorized proce[...]
 
LSP co-leads €60 million Series A financing in Muna Therapeutics
Proceeds dedicated to the development of novel small molecule therapeutics for neurodegenerative diseases Innovative drug discovery platf[...]

2021


LSP co-leads € 40 million ($ 46.3 million) Series A in Egle Therapeutics
Egle will develop first-in-class immunotherapies targeting suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases Series A financing co-led by LSP and Bpifrance, through its InnoBio 2 Fun [...]
MD Anderson and SNIPR BIOME collaborate
to advance next-generation CRISPR microbiome therapeutics   Research focused on improving immunotherapy-related side effects for patients with cancer     Amsterdam, The Netherlands, 13 September [...]
LSP invests in $83 Million Series A Financing of Evommune
To advance Development of a Unique Chronic Inflammation Pipeline Series A Comprises a Global Syndicate o Investors Including LSP, Pivotal bioVenture Partners and Andera Partners   Amsterdam, The N [...]
LSP portfolio company Nouscom announces
first patient dosed in a Phase 1b Trial with NOUS-PEV, a novel personalized cancer immunotherapy, in advanced melanoma or lung cancer   Amsterdam, The Netherlands, 25 August 2021 - LSP, one of Europe’s lead [...]
LSP Portfolio Company Cardior Announces €64 M Series B Financing
Oversubscribed round enables late-stage clinical development of lead candidate, a micro-RNA-132 inhibitor, in heart failure and further accelerates pipeline expansion   Munich, Germany, August 25, 2021 [...]
LSP leads $20 million financing of Visus Therapeutics
to advance clinical and commercial development of BRIMOCHOL™ for presbyopia     Amsterdam, The Netherlands, 10 August 2021 – LSP, one of the leading life sciences and health care investors, today ann [...]


2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to news overview
Follow us

Archive

HIGHLIGHTS

 
LSP co-leads € 40 million ($ 46.3 million) Series A in Egle Therapeutics
Egle will develop first-in-class immunotherapies targeting suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases Series A financing co-led by LSP and Bpifrance, through its InnoBio 2 Fun[...]
 
MD Anderson and SNIPR BIOME collaborate
to advance next-generation CRISPR microbiome therapeutics   Research focused on improving immunotherapy-related side effects for patients with cancer     Amsterdam, The Netherlands, 13 September[...]
 
LSP invests in $83 Million Series A Financing of Evommune
To advance Development of a Unique Chronic Inflammation Pipeline Series A Comprises a Global Syndicate o Investors Including LSP, Pivotal bioVenture Partners and Andera Partners   Amsterdam, The N[...]
 
LSP Portfolio Company Cardior Announces €64 M Series B Financing
Oversubscribed round enables late-stage clinical development of lead candidate, a micro-RNA-132 inhibitor, in heart failure and further accelerates pipeline expansion   Munich, Germany, August 25, 2021 [...]
 
LSP portfolio company Nouscom announces
first patient dosed in a Phase 1b Trial with NOUS-PEV, a novel personalized cancer immunotherapy, in advanced melanoma or lung cancer   Amsterdam, The Netherlands, 25 August 2021 - LSP, one of Europe’s lead[...]
 
LSP leads $20 million financing of Visus Therapeutics
to advance clinical and commercial development of BRIMOCHOL™ for presbyopia     Amsterdam, The Netherlands, 10 August 2021 – LSP, one of the leading life sciences and health care investors, today ann[...]
 
LSP Invests in $110 Million Series B Financing of T-knife Therapeutics
Plan to initiate the IMAG1NE Phase 1/2 clinical study of TK-8001, a TCR-T cell therapy for MAGE-A1 positive solid tumors, in 2021    Munich, Germany – August 2, 2021 – LSP, one of the leading life [...]
 
LSP Portfolio Company Artios Announces $ 153 Million (£ 110 Million) Series C Financing
Funding propels Artios’ ability to progress beyond synthetic lethality and to continue the exploitation of the full spectrum of oncology vulnerabilities presented by the DNA Damage Response through deployment of[...]
 
LSP’s Portfolio Company XyloCor Therapeutics Commences Phase 2 Component
of Phase 1/2 EXACT Clinical Study of XC001 Gene Therapy for Refractory Angina   Independent Data Monitoring Committee authorized proceeding to Phase 2 at highest dose level tested following review of clin[...]
 
LSP co-leads €60 million Series A financing in Muna Therapeutics
Proceeds dedicated to the development of novel small molecule therapeutics for neurodegenerative diseases Innovative drug discovery platform leveraging insights from novel targets and pathways, resilience to[...]

2021


LSP co-leads € 40 million ($ 46.3 million) Series A in Egle Therapeutics
Egle will develop first-in-class immunotherapies targeting suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases Series A financing co-led by LSP and Bpifrance, through its InnoBio 2 Fun [...]
MD Anderson and SNIPR BIOME collaborate
to advance next-generation CRISPR microbiome therapeutics   Research focused on improving immunotherapy-related side effects for patients with cancer     Amsterdam, The Netherlands, 13 September [...]
LSP invests in $83 Million Series A Financing of Evommune
To advance Development of a Unique Chronic Inflammation Pipeline Series A Comprises a Global Syndicate o Investors Including LSP, Pivotal bioVenture Partners and Andera Partners   Amsterdam, The N [...]
LSP portfolio company Nouscom announces
first patient dosed in a Phase 1b Trial with NOUS-PEV, a novel personalized cancer immunotherapy, in advanced melanoma or lung cancer   Amsterdam, The Netherlands, 25 August 2021 - LSP, one of Europe’s lead [...]
LSP Portfolio Company Cardior Announces €64 M Series B Financing
Oversubscribed round enables late-stage clinical development of lead candidate, a micro-RNA-132 inhibitor, in heart failure and further accelerates pipeline expansion   Munich, Germany, August 25, 2021 [...]
LSP leads $20 million financing of Visus Therapeutics
to advance clinical and commercial development of BRIMOCHOL™ for presbyopia     Amsterdam, The Netherlands, 10 August 2021 – LSP, one of the leading life sciences and health care investors, today ann [...]


2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
back to news overview